4.7 Article

Proteomic Comparison of Bone Marrow Derived Osteoblasts and Mesenchymal Stem Cells

Journal

Publisher

MDPI
DOI: 10.3390/ijms22115665

Keywords

bone marrow; osteoblast; mesenchymal stem cell; proteome; in vitro culture; ex vivo handling

Funding

  1. Norwegian Cancer Society [100933]
  2. Research Council of Norway INFRASTRUKTUR-program [295910]

Ask authors/readers for more resources

Although the proteomic profiles of osteoblasts and MSCs show many similarities, there are still several specific differences, including extracellular matrix proteins and intracellular signaling networks. Targeting these specific proteins therapeutically may have minor effects on MSCs, and careful standardization of ex vivo handling will be required for the clinical use of cultured osteoblasts/MSCs.
Mesenchymal stem cells (MSCs) can differentiate into osteoblasts, and therapeutic targeting of these cells is considered both for malignant and non-malignant diseases. We analyzed global proteomic profiles for osteoblasts derived from ten and MSCs from six healthy individuals, and we quantified 5465 proteins for the osteoblasts and 5420 proteins for the MSCs. There was a large overlap in the profiles for the two cell types; 156 proteins were quantified only in osteoblasts and 111 proteins only for the MSCs. The osteoblast-specific proteins included several extracellular matrix proteins and a network including 27 proteins that influence intracellular signaling (Wnt/Notch/Bone morphogenic protein pathways) and bone mineralization. The osteoblasts and MSCs showed only minor age- and sex-dependent proteomic differences. Finally, the osteoblast and MSC proteomic profiles were altered by ex vivo culture in serum-free media. We conclude that although the proteomic profiles of osteoblasts and MSCs show many similarities, we identified several osteoblast-specific extracellular matrix proteins and an osteoblast-specific intracellular signaling network. Therapeutic targeting of these proteins will possibly have minor effects on MSCs. Furthermore, the use of ex vivo cultured osteoblasts/MSCs in clinical medicine will require careful standardization of the ex vivo handling of the cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available